Klarogen Biotherapeutics

Klarogen Biotherapeutics is a preclinical-stage biotechnology company dedicated to developing novel therapies that harness the power of regulatory T cells (Tregs) to treat autoimmune and inflammatory diseases. Founded by Dr. Michael Rosenblum, a leading expert in Treg biology from UCSF, the company focuses on tissue-resident Tregs and their role in maintaining immune homeostasis and promoting tissue repair. Klarogen's platform aims to create targeted treatments that restore balance to the immune system without the broad immunosuppression associated with current standards of care. By focusing on the unique functions of Tregs within specific tissues, the company seeks to address the underlying causes of chronic inflammation. Klarogen is currently advancing a pipeline of biologic candidates designed to selectively enhance Treg activity in diseased environments.